A Gender Paradox in Fibrinolysis; PPIs and Hip Fracture: Evaluating the Risk; How Long Do the Effects of Tyrosine Kinase Inhibitors Last?

Women are almost twice as likely as men to suffer moderate or severe bleeding when treated with fibrinolysis for ST-segment elevation myocardial infarction (STEMI), according to researchers from the Duke Clinical Research Institute, Durham, North Carolina; the University Hospital, Leuven, Belgium; the New York University, New York, New York; the Auckland City Hospital, Auckland, New Zealand; and the Scripps Clinic, San Diego, California. On the other hand, women have a lower risk of death due to bleeding.